Item 5.02 Departure of Directors or Certain Officer; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) Effective February 16, 2021, Dr. Felix Baker resigned as a member of the
Board of Directors of Alexion Pharmaceuticals, Inc. (the "Company"). Dr. Baker's
resignation was not because of any disagreement with the Company on matters
relating to its operations, policies or practices. Dr. Baker made the following
statement in connection with his decision to resign from the Board, "I
appreciate the opportunity to have served as a director of Alexion
Pharmaceuticals since 2015 and am proud of the significant progress we made
advancing the company's mission of developing and delivering transformative
medicines for people with rare diseases and devastating conditions. I fully
support the company's strategy, including the transaction with AstraZeneca, and
voted in favor of the Merger Agreement and the transaction."
--------------------------------------------------------------------------------
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: February 16, 2021 ALEXION PHARMACEUTICALS, INC.
By: /s/ Doug Barry
Name: Doug Barry
Title: Vice President, Corporate Law
© Edgar Online, source Glimpses